Fig 1: Correlation analysis between KIF4A and CDC5L by bioinformatic analysis. (a) Mechanism diagram of gene interaction between KIF4A and BRCA1, BRCA2, and CDC5L by GeneCards. (b) Correlation analysis of the expression of KIF4A and BRCA1, BRCA2, and CDC5L by GEPIA.
Fig 2: The expression of KIF4A is correlated with CDC5L in tumor tissues of pancreatic cancer. Representative images of immunohistochemical staining of KIF4A and CDC5L expression in tumor tissues.
Fig 3: KIF4A knockdown inhibits cell migration or invasion. (a) Scratch test in PANC-1 and BxPC-3 cells. The distance between edges in the shRNA group was wider than controls (P < 0.05, respectively). (b) Transwell assay in PANC-1 and BxPC-3 cells. The ability of invasion in the shRNA group was decreased significantly (P < 0.05, respectively). All results were performed in three independent experiments. ∗P < 0.05.
Fig 4: Bioinformatic analysis of KIF4A in cases from TCGA. (a) The expression of KIF4A between cancer (n = 179) and normal (n = 171) cases, cancer cases were filled in red, and normal cases were in blue: KIF4A expression was significantly increased in pancreatic tumor tissue compared with normal pancreatic tissue (P < 0.05). ∗P < 0.05. (b) The overall survival and disease-free survival rate of 178 TCGA cases with clear clinical information. High and low groups were divided by median and filled in red and blue, respectively. Comparing with the lower expression cases, patients with higher level of KIF4A shared a significantly worse disease-free survival and overall survival (P < 0.05, respectively).
Fig 5: In vivo KIF4A knockdown inhibits tumor growth. (a, b) Tumor volume in the KIF4A knockdown and control nude mouse group after 4 weeks, respectively. From growth curve, tumors in the shRNA group grew more slowly than controls and tumor volumes were smaller in the shRNA group (P < 0.05, respectively). (c, d) Knockdown efficiency tested by western blot and immunohistochemistry, and the boxplot results were shown in the following, respectively. The expression of KIF4A in mouse tumors was dramatically decreased by immunohistochemistry and western blot (P < 0.05, respectively). All results were performed in three independent experiments. ∗P < 0.05.
Supplier Page from OriGene Technologies for KIF4A Human shRNA Lentiviral Particle (Locus ID 24137)